Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol;Réduction du risque métabolique associé à l'obésité en modulant l'exposition tissulaire au cortisol

Revue Medicale Suisse

Volumn 6, Issue 260, 2010, Pages 1608-1612

  Iovino, Alessandra ^a   Paquot, N ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; HYDROCORTISONE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ENZYME INHIBITOR;

ABDOMINAL OBESITY; CUSHING SYNDROME; DYSLIPIDEMIA; ENZYME INHIBITION; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; METABOLIC SYNDROME X; OBESITY;

EID: 77956588453     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52-63.
2. Iovino A, Scheen AJ. Moduler l'exposition tissulaire au cortisol, nouvelle perspective pour réduire le risque métabolique associé à l'obésité. Rev Med Liège 2010;65:140-6.
3. ** Tomlinson JW, Walker EA, Bujalska IJ, et al. 11-β-hydroxysteroïd dehydrogenase type I: A tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66.
4. Björntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000;16:924-36.
5. * Anagnostis P, Athyros VG, Tziornalos K, et al. The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis. J Clin Endocrinol Metab 2009;94:2692-701.
6. Bujalska IJ, Draper N, Michailidou Z, et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11-β-hydoxysteroid dehydrogenase type I. J Mol Endocrinol 2005;34:675-84.
7. Bujalska IJ, Walker EA, Hewison M, et al. A switch in dehydrogenase to reductase activity of 11-β-hydroxysteroid dehydrogenase type I upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002;87:1205-10. (Pubitemid 36121089)
8. Iovino A, Paquot N, Scheen AJ. Rôle de l'enzyme 11-β-hydroxydéshydrognéase de type I dans le risque métabolique associé à l'obésité. Obésité 2009;4:181-8.
9. * Stulnig TM, Waldhäusl W. 11-β-hydroxysteroid dehydrogenase type I in obesity and type 2 diabetes. Diabetologia 2004;47:1-11.
10. * Walker BR, Andrew R. Tissue production of cortisol by 11-β-hydroxysteroid dehydrogenase type I and metabolic disease. Ann NY Acad Sci 2006;1083:165-84.
11. London E, Castonguay TW. Diet and the role of 11-β-hydroxysteroid dehydrogenase-1 on obesity. J Nutr Biochem 2009;20:485-93.
12. Iwasaki Y, Takayasu S, Nishiyama M, et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11-β-hydroxysteroid dehydrogenase type I) gene. Mol Cell Endocrinol 2008;285:10-8.
13. re partie: rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité. Méd Malad Métab 2009;3:507-13.
14. e partie: Inhibition sélective pour traiter les anomalies métaboliques associées à l'obésité. Méd Malad Métab 2009;3:595-600.
15. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect «Cushing's disease of the omentum»? Lancet 1997;349:1210-3.
16. Tomlinson JW, Stewart PM. «Cushing's disease of the omentum» - fact or fiction? J Endocrinol Invest 2004;27:171-4.
17. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11-β-hydroxysteroid dehydrogenase type I in humans. Diabetes 2009;58:46-53.
18. Swali A, Walker EA, Lavery GG, et al. 11-β-hydroxysteroid dehydrogenase type I regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 2008;51:2003-11.
19. Berthlaume M, Laplante M, Festuccia WT, et al. Additive action of 11beta-HSDI inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes 2009;33:601-4.
20. Edgerton DS, Basu R, Ramnanan CJ, et al. Effect of 11-β- hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab 2010;298:E1019-26.
21. Stewart PM, Tomlinson JW. Selective inhibitors of 11-β- hydroxysteroid dehydrogenase type I for patients with metabolic syndrome, is the target liver, fat, or both? (commentary). Diabetes 2009;58:14-5.
22. Valsamakis G, Anwar A, Tomlinson JW, et al. 11-β-hydroxysteroid dehydrogenase type I activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:4755-61.
23. Wamil M, Seckl JR. Inhibition of 11-β-hydroxysteroid dehydrogenase type I as a promising therapeutic target Drug Discov Today 2007;12:504-20.
24. * Ge R, Huang Y, Liang G, Li X. 11-β-hydroxysteroid dehydrogenase type I inhibitors as promising therapeutic drugs for diabetes: Status and development. Cur Med Chem 2010;17:412-22.
25. Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11 oxosteroid-reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80:3155-9.
26. Andrews RC, Rooyackers O, Walker B. Effects of the 11-β- hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-91. (Pubitemid 36115179)
27. Boyle CD, Kowalski TJ. 11-β-hydroxysteroid dehydrogenase type I inhibitors: A review of recent patents. Exp Opin Ther Pat 2009;19:801-25.
28. Tiwari A. INCB-13739, an 11-β-hydroxysteroid dehydrogenase type I inhibitor for the treatment of type 2 diabetes. IDrugs 2010;13:266-75.
29. Hawkins M, Hunter D, Kishore P, et al. INCB013739, a selective inhibitor of 11-β-hydroxysteroid dehydrogenase type I (11βHSDI), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus (Abstran). Diabetes 2008; 57(Suppl. I):A99-A100.
30. * Rosenstock J, Banarer S, Fonseca V, et al. Inhibition of 11βHSDI in type 2 diabetes. Diabetes Care 2010;33:1516-21
31. Shah U, Boyle CD, Chackalamannil S, et al. Azabicyclic sulfonamides as potent 11beta-HSDI inhibitors. Bioorg Med Chem Lett 2010;20:1551-4.
32. Odermatt A, Nashev LG. The glucocorticoid-activating enzyme 11-β-hydroxysteroid dehydrogenase type I has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 2010;119:1-13.
33. * Vantyghem M-C, Marcelli-Tourvieille S, Defrance F, et al. 11-β-hydroxystéroide déshydrogénases. Avancées récentes. Ann Endocrinol Paris 2007;68:349-56.
34. Strachan MWJ, Reynolds RM, Frier BM, et al. The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes Metab 2009;11:407-14.
35. Ergang P, Leden P, Vagnerova K, et al. Local meta-bolism of glucocorticoids and its role in rat adjuvant arthritis. Mol Cell Endocrinol 2010;323:155-60.